Key Highlights

  • Nuvation Bio secured FDA approval for a supplemental New Drug Application revising the label for IBTROZI.
  • The update incorporates a 49.7-month median duration of response from the TRUST-I study.
  • The data covers TKI-naive ROS1-positive non-small cell lung cancer patients.
  • Extended monitoring revealed no novel safety concerns or safety labeling modifications.

Nuvation Bio Inc. (NYSE: NUVB) secured FDA approval for a supplemental New Drug Application revising the label for IBTROZI, incorporating a 49.7-month median duration of response from the TRUST-I study in TKI-naive ROS1-positive non-small cell lung cancer.

Company Overview

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing therapies for cancer patients with high unmet medical needs. Its lead commercial product, IBTROZI (taletrectinib), is a ROS1 tyrosine kinase inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer, representing the company's transition from a clinical-stage developer to a commercial-stage oncology company.

The company has continued to generate additional long-term efficacy and safety data supporting IBTROZI's label following its initial approval, an important part of building physician and payer confidence in a newly commercialized oncology product as it competes for Market Share against other ROS1-targeted therapies.

What Happened

Extended monitoring revealed no novel safety concerns or modifications to safety labeling, solidifying IBTROZI's position four months prior to the scheduled PDUFA target date for a related regulatory decision.

Market Reaction

The disclosed information does not include stock price or trading data for Nuvation Bio following the label update approval.

Outlook

The scheduled PDUFA target date, now four months away, represents the next major disclosed regulatory milestone for Nuvation Bio related to IBTROZI.